Summary
Bristol-Myers Squibb Company (BMY) filed an amendment to its 2001 Annual Report on Form 10-K, primarily to restate its financial statements for the years ended December 31, 2001, 2000, and 1999. The restatement was necessitated by a substantial buildup of wholesaler inventories in its U.S. pharmaceuticals business, driven by sales incentives offered to meet quarterly sales projections. This led to a determination that certain sales to two major wholesalers should have been accounted for under the consignment model, correcting errors in revenue recognition timing. The company also corrected other historical accounting policies and identified known errors previously deemed immaterial. These restatements reduced net earnings for 2001, 2000, and 1999 by approximately $411 million, $240 million, and $366 million, respectively. The company has implemented significant internal control improvements, including hiring a new CFO, restructuring its accounting department, and enhancing monitoring processes to prevent future recurrences.
Key Highlights
- 1The company restated its financial statements for fiscal years 2001, 2000, and 1999 due to errors in revenue recognition timing related to wholesaler inventory build-ups and sales incentives.
- 2Certain sales to two major U.S. pharmaceuticals wholesalers were reclassified to the consignment model, impacting revenue recognition and net sales figures.
- 3The restatement reduced reported net earnings by $411 million (2001), $240 million (2000), and $366 million (1999).
- 4The company identified two material weaknesses in its internal controls related to accounting and financial reporting.
- 5Significant management changes and control enhancements were implemented, including hiring a new CFO, restaffing the controller position, and creating a chief compliance officer role.
- 6The company completed the divestiture of its Clairol business and the spin-off of Zimmer Holdings, Inc. in 2001, and acquired the DuPont Pharmaceuticals business for $7.8 billion.
- 7The company is facing significant litigation, including antitrust cases related to TAXOL® and BUSPAR, with proposed settlements totaling $135 million and $535 million, respectively.